Breaking News

Inside the staff exodus and tanking morale that threaten Makary’s FDA 

July 7, 2025
Pharmalot Columnist, Senior Writer
FDA Commissioner Marty Makary has insisted that agency morale is "good and improving," but employees told STAT it is incredibly low.
Jose Luis Magana/AP

STAT+ | Inside the staff exodus and tanking morale that threaten Makary's FDA

FDA staff are already missing deadlines, and the future consequences could be even more dire as workers head for the exits.

By Lizzy Lawrence


STAT+ | As Chinese-developed drugs draw U.S. interest, a regulatory chill threatens to dampen new investment

A pair of recent announcements by the FDA suggest the agency is focused on national political priorities and has a suspicion of 'hostile countries.'

By Brian Yang


STAT+ | Apogee reports first data on long-acting eczema drug

The antibody treatment alleviated the signs and symptoms of atopic dermatitis far more than a placebo — achieving the efficacy goals of a clinical trial.

By Adam Feuerstein



An illustration of a mast cell, part of the human immune system.
Adobe

STAT+ | Cogent Biosciences drug improves symptoms of chronic immune disorder, study results show

The drug, bezuclastinib, reduced the symptoms of a chronic immune disorder called indolent systemic mastocytosis in a Phase 2 trial.

By Adam Feuerstein


Leading medical groups sue Kennedy over changed Covid-19 vaccine recommendations

Lawsuit says Kennedy's changes are 'contrary to the wealth of data and peer-reviewed studies that demonstrate the safety and efficacy of Covid vaccines'

By Chelsea Cirruzzo


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments